Pharmacokinetic (PK) analysis of a phase I trial investigating continuous treatment with the angiokinase inhibitor BIBF 1120 combined with pemetrexed in previously treated patients with non-small cell lung cancer (NSCLC) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hanna, NH
  • Zhao, Y
  • Kaiser, R
  • Stopfer, P
  • Gyorffy, S
  • Ellis, Peter

publication date

  • May 20, 2008